← Back to Search

Proactive Navigator-Assisted Cessation Program for Smoking Cessation (EMPACT-Us Trial)

N/A

Recruiting

Led By Karim Ghobrial-Sedky, MD, MSc, DFAPA

Research Sponsored by Family Health Centers of San Diego

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 to 35 months

Awards & highlights

EMPACT-Us Trial Summary

This trial tests a new method of helping people quit smoking. It hopes to improve engagement in treatments, quit attempts and quitting success.

Who is the study for?

This trial is for current tobacco users who are at least 18 years old, of any ethnicity, race, nationality, sexual orientation or mental health status. They must speak English or Spanish and have met level 1 criteria for inclusion. It's not open to those with lung cancer or pregnant/breastfeeding women.Check my eligibility

What is being tested?

The study tests EMPACT-Us, a set of services designed to help low-income patients quit smoking. Its effectiveness will be compared against enhanced usual care by measuring engagement in treatments and verified cessation rates at 6 and 12 months.See study design

What are the potential side effects?

Since this trial involves behavioral interventions rather than medications, typical drug side effects aren't expected. However, participants may experience stress or discomfort related to quitting smoking.

EMPACT-Us Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 to 35 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 to 35 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 to 35 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Biochemically verified tobacco-use cessation as assessed through cotinine saliva test

Engagement with tobacco-use treatment as captured through Electronic Health Record queries

Tobacco-use quit attempts as assessed through Electronic Health Record queries

EMPACT-Us Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: EMPACT-UsExperimental Treatment1 Intervention

An innovative suite of tobacco cessation services designed in partnership with patients, providers, and other community stakeholders during a pilot study.

Group II: Newly-enhanced usual care (EUC)Active Control1 Intervention

Newly-enhanced usual care (EUC)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Family Health Centers of San DiegoLead Sponsor

6 Previous Clinical Trials

1,077 Total Patients Enrolled

University of California, San DiegoOTHER

1,122 Previous Clinical Trials

1,507,548 Total Patients Enrolled

Tobacco Related Disease Research ProgramOTHER

25 Previous Clinical Trials

7,122 Total Patients Enrolled

Media Library

EMPACT-Us Clinical Trial Eligibility Overview. Trial Name: NCT05750537 — N/A

Quitting Smoking Research Study Groups: Newly-enhanced usual care (EUC), EMPACT-Us

Quitting Smoking Clinical Trial 2023: EMPACT-Us Highlights & Side Effects. Trial Name: NCT05750537 — N/A

EMPACT-Us 2023 Treatment Timeline for Medical Study. Trial Name: NCT05750537 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enlistment open for this test?

"According to the latest updates on clinicaltrials.gov, this trial is no longer recruiting participants as of February 28th 2023. Nonetheless, 24 other trials are currently open for enrollment at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients

2023. "Enhanced Multicomponent Proactive Navigator-Assisted Cessation of Tobacco Use in Low-Income Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05750537.